[HTML][HTML] Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations
Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …
Epidermal growth factor receptor inhibition in mutation-positive non–small-cell lung cancer: is afatinib better or simply newer?
CJ Langer - Journal of Clinical Oncology, 2013 - ascopubs.org
In the last decade we have witnessed a major evolution in both molecular diagnostics and
individualized therapy in the management of advanced non–small-cell lung cancer …
individualized therapy in the management of advanced non–small-cell lung cancer …
Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
I Sullivan, D Planchard - Frontiers in medicine, 2017 - frontiersin.org
Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung …
YT Lin, JS Chen, WY Liao, CC Ho… - … Journal of Cancer, 2019 - Wiley Online Library
Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …
[HTML][HTML] Activity of afatinib in heavily pretreated patients with ERBB2 mutation–positive advanced NSCLC: findings from a global named patient use program
Abstract Introduction Approximately 1% to 4% of NSCLC tumors harbor erb-b2 receptor
tyrosine kinase 2 (ERBB2) mutation; there is no approved targeted treatment for this …
tyrosine kinase 2 (ERBB2) mutation; there is no approved targeted treatment for this …
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
MJ Hochmair, A Morabito, D Hao, CT Yang… - Future …, 2018 - Taylor & Francis
Aim: To assess outcomes in patients with EGFR mutation-positive (Del19, L858R) non-small-
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …
cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting …